USARIEM
Natick, Massachusetts, 01760, United States
NCT Number: NCT04111263
The aim of this randomized, crossover clinical trial is to determine the efficacy of a gut microbiota-targeted nutritional intervention containing a blend of fermentable fibers and polyphenols (FP) for mitigating increases in GI permeability, and decrements in immune function and neuropsychologic performance following rapid ascent to simulated high altitude. Fifteen healthy young adults will participate in each of three study phases that include a 14-day supplementation period in which participants will consume 1 of 2 supplement bars: placebo (PL, will be consumed during 2 phases) and FP supplementation (will be consumed during one phase only). During the final 2-d of each phase, participants will live in a hypobaric chamber under sea level or high altitude conditions.
Looking for future studies?
Notify Me17 year–39 year
All sexes
Interventional
Not applicable
Natick, Massachusetts, 01760, United States
The collection of microbes inhabiting the human gastrointestinal (GI) tract, known as the gut microbiota, is increasingly recognized as a mediator of GI, immunologic, and neuropsychologic responses to various environmental and physiologic stressors. The hypobaric hypoxia characteristic of high altitude environments is a stressor that has recently been associated with increased GI permeability, and which has been shown to cause decrements in immune, neuropsychological and physical function. To what extent modulation of the human gut microbiota can mitigate these responses during high altitude exposure is undetermined. The aim of this randomized, crossover clinical trial is to determine the efficacy of a gut microbiota-targeted nutritional intervention containing a blend of fermentable fibers and polyphenols (FP) for mitigating increases in GI permeability, and decrements in immune function and neuropsychologic performance following rapid ascent to simulated high altitude. Fifteen healthy young adults will participate in each of three study phases in random order. Each phase will include a 14-day supplementation period in which participants will consume 1 of 2 supplement bars: placebo (PL, will be consumed during 2 phases) and FP supplementation (will be consumed during one phase only). During the final 2-d of each phase, participants will live in a hypobaric chamber. During one phase the chamber environment will mimic low-altitude conditions (SHAM). During two phases the chamber environment will mimic the barometric pressure at Pike's Peak CO (460 mmHg; HA).
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Fiber and polyphenol blend
Matched placebo
Simulated high altitude in altitude chamber using hypobaric hypoxia
Sea level environment in altitude chamber
Time frame: Study days 20, 40 and 60
Intestinal permeability measured by the ratio of the urinary excretion of sucralose and erythrirol
Time frame: Study days 20, 21, 41, 42, 62, 63
Fasting serum lipopolysaccharide binding protein concentration
Time frame: Study days 20, 21, 41, 42, 62, 63
Fasting serum zonulin concentration
Time frame: Study days 20, 21, 41, 42, 62, 63
Fasting serum glucagon-like peptide-2 concentration
Time frame: Study days 20, 21, 41, 42, 62, 63
Fasting and post-exercise serum intestinal fatty acid binding protein concentration
Time frame: Study days 20, 21, 41, 42, 62, 63
Fasting and post-exercise serum claudin-3 concentration
Time frame: Study days 20, 21, 41, 42, 62, 63
Fasting and post-exercise serum S100B concentration
Time frame: Study days 20, 21, 41, 42, 62, 63
Fasting serum interleukin (IL) IL-6, IL-8, IL-10, IL-17, IL-1β, IL-1ra, tumor necrosis factor-α, interferon-γ concentrations
Time frame: Study days 6, 18, 21, 23, 27, 39, 42, 44, 48, 60, 63, 65
Fecal calprotectin concentration
Time frame: Study days 20, 21, 41, 42, 62, 63
Fasting and post-exercise serum glucose concentrations
Time frame: Study days 20, 21, 41, 42, 62, 63
Fasting and post-exercise serum insulin concentrations
Time frame: Study days 20, 21, 41, 42, 62, 63
Fasting and post-exercise serum lactate concentrations
Time frame: Study days 20, 21, 41, 42, 62, 63
Fasting and post-exercise serum glycerol concentrations
Time frame: Study days 20, 21, 41, 42, 62, 63
Fasting and post-exercise serum cortisol concentrations
Time frame: Study days 20, 41, 62
Fasting serum bone specific alkaline phosphatase concentration
Time frame: Study days 20, 41, 62
Fasting serum carboxy-terminal collagen crosslinks concentration
Time frame: Study days 20, 41, 62
Fasting serum tartrate resistant acid phosphatase concentration
Time frame: Study days 20, 41, 62
Fasting serum procollagen type 1 N-terminal propeptide concentration
Time frame: Study days 20, 41, 62
Fasting serum osteocalcin concentration
Time frame: Study days 20, 21, 41, 42, 62, 63
Secretory immunoglobulin A concentrations in tear fluid and saliva
Time frame: Study days 21, 42, 63
Immune cell phenotype by flow cytometry
Time frame: Study days 21, 42, 63
T-cell simulated cytokine production by cell culture and flow cytometry
Time frame: Study days 21, 42, 63
Natural killer-cell cytotoxicity by cell culture and flow cytometry
Time frame: Study days 20, 21, 41, 42, 62, 63
Environmental Symptoms Questionnaire-short form. Acute Mountain Sickness will be measured multiple times daily using the Lake Louise scoring system wherein higher scores indicate more severe symptoms. AMS severity cutoffs will use mild (0.7-1.53), moderate (1.53-2.63), severe >=2.63
Time frame: Study weeks 0, 1, 2, 3, 4, 5, 6, 7, 8, 9
Gastrointestinal symptoms measure by modified version of the gastrointestinal quality of life index wherein lower scores indicate more severe symptoms.
Time frame: Study weeks 0, 1, 2, 3, 4, 5, 6, 7, 8, 9
Gastrointestinal symptoms measure by modified version of the irritable bowel syndrome symptom severity scale score wherein higher scores indicate more severe symptoms. Scored on scale of 0-500; symptom severity scored as mild (75-174), moderate (175-300), severe (>300).
Time frame: Study weeks 0, 1, 2, 3, 4, 5, 6, 7, 8, 9
Hunger, fullness, desire to eat, and prospective consumption measured by 100 mm visual analog scale. Scored from 0-100 with higher scores indicating greater sensation.
Time frame: Study days 20, 21, 41, 42, 62, 63
Measured by Profile of Mood States Questionnaire; a 65-item inventory of self-reported mood states which factor into six mood sub-scales (tension/anxiety (0-36), depression/dejection (0-60), anger/hostility (0-48), vigor/activity (0-32), fatigue/inertia (0-28), confusion/bewilderment (0-28), and total mood disturbance (0-200) wherein higher scores indicate greater mood state.
Time frame: Study days 20, 21, 41, 42, 62, 63
Measured by Feeling Scale; a one-item inventory measuring the extent to which participants feel pleasant or unpleasant. Higher scores indicate more unpleasant feeling. Scored from -5 (very bad) to 5 (very good)
Time frame: Study days 20, 21, 41, 42, 62, 63
Measured by Felt Arousal Scale; a one-item inventory measuring the extent to which participants feel aroused. Higher scores indicate greater arousal (low=1 to high =6).
Time frame: Study days 20, 21, 41, 42, 62, 63
Measured by Evaluation of Risks Questionnaire; a 24-item questionnaire providing scores on five scales: self-control, danger seeking, energy, impulsivity, and invincibility.
Time frame: Study days 7, 20, 21, 41, 42, 62, 63
Measured by Balloon Analogue Risk Task
Time frame: Study days 7, 21, 42, 63
Resting metabolic rate measured by indirect calorimetry
Time frame: Study days 20, 21, 41, 42, 62, 63
Energy expenditure measured by indirect calorimetry during 60-minute steady state exercise
Time frame: Study days 20, 41, 62
Gastric, small intestine and large intestine transit time measured by SmartPill
Time frame: Study days 20, 41, 62
Gastric, small intestine and large intestine pH measured by SmartPill
Time frame: Study days 20, 21, 41, 42, 62, 63
Measured by N-Back task before, during and after exercise
Time frame: Study days 20, 21, 41, 42, 62, 63
Measured by emotional Interference task before, during and after exercise
Time frame: Study days 20, 21, 41, 42, 62, 63
Measured by Matching to Sample test in the morning and afternoon
Time frame: Study days 20, 21, 41, 42, 62, 63
Measured by reaction time task before, during and after exercise
Time frame: Study days 20, 21, 41, 42, 62, 63
Measured by Go/No-Go task before, during and after exercise
Time frame: Study days 20, 21, 23, 41, 42, 44, 62, 63, 65
Measured by scanning visual vigilance task
Time frame: Study days 20, 21, 23, 41, 42, 44, 62, 63, 65
Measured by psychomotor vigilance test
Time frame: Study days 20, 21, 23, 41, 42, 44, 62, 63, 65
Measured by grammatical Reasoning task
Time frame: 48-hours/day during study weeks 0, 2, 3, 5, 6, 8, 9
Measured by wrist-worn vigilance monitor
Time frame: Study days 6, 18, 21, 23, 27, 39, 42, 44, 48, 60, 63, 65
Fecal short chain fatty acid concentrations
Time frame: Study days 6, 18, 21, 23, 27, 39, 42, 44, 48, 60, 63, 65
Fecal bacterial community diversity and relative abundance measured by 16S rRNA gene sequencing
Time frame: Study days 20, 21, 41, 42, 62, 63
Fasting and post-exercise circulating and exosomal microRNA
United States Army Research Institute of Environmental Medicine
Fed
Efficacy of a Gut-microbiota Targeted Nutritional Intervention for Promoting Gut Barrier Integrity During Short-term Exposure to Hypobaric Hypoxia.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02127164
Complicated Diverticulitis, Gastrointestinal Injury
Tucson, Arizona, United States
View Trial DetailsNCT03198741
Cardiovascular Diseases, Gastrointestinal Injury
Shenyang, Liaoning, China
View Trial DetailsNCT05951517
Blood Coagulation Disorders, Cardiovascular Diseases
Guangzhou, Guangdong, China
View Trial DetailsNCT06499714
Acute Mountain Sickness, Altitude Sickness
Bishkek, Kyrgyzstan
View Trial Details